Thursday, November 14, 2024
HomeLatest Pharma-NewsTWILIGHT trial showed that Brilinta (ticagrelor) monotherapy reduced the risk of clinically...

TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT) in patients with non-ST elevation acute coronary syndromes (NSTE-ACS)

Nov 17, 2019: From subgroup analysis of the TWILIGHT trial in patients with non-ST elevation acute coronary syndromes(NSTE-ACS), Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT).

NSTE-ACS subgroup analysis shows results like As compared to ticagrelor plus aspirin (3.6% vs. 7.6%, HR 0.47; 95% CI: 0.36-0.61), results showed by Ticagrelor monotherapy was found to be 4.0% risk reduction in bleeding.

- Advertisement -

Likewise, Thrombolysis in Myocardial Infarction (TIMI) major bleeding at one year was found to be 0.5% for ticagrelor plus placebo and 1.0% for ticagrelor plus aspirin.

Also the death rates in one year are (1.0% for ticagrelor plus placebo and 1.5% for ticagrelor plus aspirin), MI (3.1% and 3.1%), ischemic stroke (0.5% and 0.3%), and definite or probable stent thrombosis (0.4% and 0.6%).

Rates of other secondary endpoints also were similar between the two groups at one year – all-cause death. As concluded, there was a lower risk of bleeding compared with standard 12 months of dual antiplatelet therapy with ticagrelor plus aspirin. https://www.astrazeneca.com/media-centre/medical-releases/subgroup-analysis-of-twilight-trial-patients-with-nste-acs.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular